ke-20260812
0001606757false00016067572026-08-122026-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)   August 12, 2026
keilogoonelinecolorcmyk2revi.jpg
KIMBALL ELECTRONICS, INC.
________________________________________________________________________________________________________
(Exact name of registrant as specified in its charter)
Indiana001-3645435-2047713
(State or other jurisdiction of(Commission File(IRS Employer Identification No.)
incorporation)Number)
1205 Kimball Boulevard, Jasper, Indiana
47546
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code   (812) 634-4000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each ClassTrading SymbolName of each exchange on which registered
Common Stock, no par valueKEThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02 Results of Operations and Financial Condition
On August 12, 2026, the Company issued an earnings release for the fourth quarter ended June 30, 2026. The earnings release is attached as Exhibit 99.1.
The information in Item 2.02 of this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit
NumberDescription
99.1
104Cover Page Interactive Data File (formatted in Inline XBRL)

2

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
KIMBALL ELECTRONICS, INC.
By:/s/ Jana T. Croom
JANA T. CROOM
Chief Financial Officer
Date: August 12, 2026

3





Exhibit 99.1
releaseheadinglogo.jpg
KIMBALL ELECTRONICS REPORTS Q4 RESULTS;
COMPANY PROVIDES GUIDANCE FOR FISCAL 2027 HIGHLIGHTED BY ORGANIC SALES GROWTH AND ACCRETIVE IMPACT OF THE HELVOET ACQUISITION

JASPER, Ind., August 12, 2026 -- (BUSINESS WIRE) -- Kimball Electronics, Inc. (Nasdaq: KE) today announced financial results for the fourth quarter and full fiscal year ended June 30, 2026.
“I’m proud of our results in the fourth quarter and very good finish to fiscal 2026. Sales in Q4 were in line with expectations, adjusted operating income was better than estimates, and we generated strong cash from operations, which was used to pay down debt to its lowest level in over 4 years. Our balance sheet continued to strengthen and we are actively leveraging it to make strategic investments in growth in the medical CDMO space, such as the buildout of our new medical facility in Indianapolis and the acquisition of Helvoet Polymer Technologies.

Our guidance for fiscal 2027 is highlighted by organic sales growth and the accretive impact from Helvoet. We are expecting Medical to continue to outpace the other two verticals and represent more than one-third of total Company sales in the fiscal year, which is in line with our objective to balance the portfolio across the markets we serve. Our strategic journey continues to build, and so does my excitement for the future of this Company.”

Richard D. Phillips
Chief Executive Officer
  Fourth Quarter 2026 Highlights
•Net sales of $371.6 million, a 5% sequential increase with all end-market verticals posting gains
•Operating income of $29.1 million, or 7.8% of net sales; adjusted operating income margin of 4.9% of net sales
•Cash from operations of $42.4 million, the tenth consecutive quarter of positive operating cash generation
•Debt of $116.6 million, the lowest level in over 4 years
•Cash of $88.9 million and borrowing capacity of $322.4 million
•Cash Conversion Days of 82, the best result in 17 quarters
•Invested $2.1 million to repurchase 83,000 shares of common stock
•Company provides guidance for fiscal 2027 highlighted by organic sales growth and the accretive impact of Helvoet Polymer Technologies






Net Sales by Vertical Market For Q4 Fiscal 2026
Sales in the medical vertical market increased 1% compared to the fourth quarter of fiscal 2025, while sales in the automotive and industrial vertical markets decreased 3% and 5%, respectively.
netsalesq426-updated872026.jpg
*
Percentage of net sales.
**Percentage changes compared to Q4 of fiscal 2025.







FISCAL YEAR 2026 HIGHLIGHTS
•Net sales totaled $1,431.4 million, with Medical increasing over 10%, after normalizing fiscal 2025 for a consigned inventory sale
•Operating income of $66.1 million, or 4.6% of net sales, adjusted operating income margin of 4.6% of net sales
•Cash generated from operating activities of $72.3 million
•Invested $11.9 million to repurchase 447,000 shares of common stock

“As we expected, fiscal 2026 was a year of transition and I am impressed with our team’s resilience and ability to deliver results in a challenging environment. As a CFO who takes great pride in the condition of our balance sheet, we exited the fiscal year in a position of strength, with plenty of dry powder in the form of borrowing capacity and available cash to strategically invest. Our guidance for fiscal 2027 projects a return to top line growth and we will be leveraging the balance sheet to support those efforts.”

Jana T. Croom

Chief Financial Officer

FISCAL YEAR 2027 GUIDANCE
•Net sales in the range of $1,535 - $1,560 million, a 7% - 9% increase compared to fiscal 2026
◦Organic sales growth of 3% - 5%, with Medical increasing in the high single to low double-digit range
◦Helvoet sales of approximately $60 million
•Adjusted operating income of 4.4% - 4.7% of net sales
•Capital expenditures of $50 - $60 million



webcastq426.jpg
Conference Call / Webcast

Thursday, August 13, 2026

Live Webcast:
investors.kimballelectronics.com/events-and-presentations/events

For those unable to participate in the live webcast, the call will be archived at investors.kimballelectronics.com.







Forward-Looking Statements
Certain statements contained within this release are considered forward-looking, including our guidance, under the Private Securities Litigation Reform Act of 1995. The statements may be identified by the use of words such as “expect,” “should,” “goal,” “predict,” “will,” “future,” “optimistic,” “confident,” and “believe.” Undue reliance should not be placed on these forward-looking statements. These statements are based on current expectations of future events and thus are inherently subject to uncertainty. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. These forward-looking statements are subject to risks and uncertainties including, without limitation, global economic conditions, geopolitical environment and conflicts such as war, global health emergencies, availability or cost of raw materials and components, tariffs and other trade barriers, foreign exchange rate fluctuations, and our ability to convert new business opportunities into customers and revenue. Additional cautionary statements regarding other risk factors that could have an effect on the future performance of the company are contained in its Annual Report on Form 10-K for the year ended June 30, 2025.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures. The non-GAAP financial measures contained herein include constant currency growth, net sales excluding Automation, Test & Measurement, adjusted selling and administrative expenses, adjusted operating income, adjusted EBITDA, adjusted net income, adjusted diluted EPS, and normalized sales growth. Reconciliations of the reported GAAP numbers to these non-GAAP financial measures are included in the Reconciliation of Non-GAAP Financial Measures section below. Management believes these measures are useful and allow investors to meaningfully trend, analyze, and benchmark the performance of the company’s core operations. The company’s non-GAAP financial measures are not necessarily comparable to non-GAAP information used by other companies.
About Kimball Electronics/Kimball Solutions
Kimball Electronics is a global, multifaceted manufacturer offering Electronics Manufacturing Services (EMS) and Contract Development and Manufacturing Organization (CDMO) solutions to customers around the world. From our operations in the United States, China, India, Mexico, The Netherlands, Poland, Romania, and Thailand, our teams are proud to provide manufacturing services for a variety of industries. Recognized for a reputation of excellence, we are committed to a high-performance culture that values quality, reliability, value, speed, and ethical behavior. Kimball Electronics, Inc. (Nasdaq: KE) is headquartered in Jasper, Indiana.
To learn more about Kimball Electronics, visit www.kimballelectronics.com.
Lasting relationships. Global success.
releaseheadinglogo.jpg
Contact:
Andrew D. Regrut
Vice President, Investor Relations, Strategic Development, and Treasurer
812.827.4151






Financial highlights for the fourth quarter and fiscal year ended June 30, 2026 are as follows:
Three Months Ended
Fiscal Year Ended
June 30,June 30,
(Amounts in Thousands, except EPS)2026202520262025
Net Sales$371,573 $380,472 $1,431,378 $1,486,727 
Operating Income
$29,081 $16,474 $66,057 $45,535 
Adjusted Operating Income (non-GAAP)
$18,112 $19,638 $65,735 $61,267 
Operating Income %7.8%4.3%4.6%3.1%
Adjusted Operating Income (non-GAAP) % 4.9%5.2%4.6%4.1%
Net Income $8,518 $6,581 $27,960 $16,984 
Adjusted Net Income (Loss) (non-GAAP) $(163)$8,438 $27,045 $28,156 
Diluted EPS
$0.35 $0.26 $1.13 $0.68 
Adjusted Diluted EPS (non-GAAP)
$(0.01)$0.34 $1.09 $1.12 


Net Sales by Vertical Market for Q4 and Full Year Fiscal 2026:
Three Months Ended
Fiscal Year Ended
June 30,June 30,
(Amounts in Millions)
2026
*
2025 (2)
*Percent
Change
2026
*
2025 (2)
*Percent Change
Automotive
$169.7 46%$175.0 46%(3)%$656.9 46%$708.5 47%(7)%
Medical
108.8 29%107.2 28%1%412.8 29%396.2 27%4%
Industrial excluding AT&M (1)
93.1 25%98.3 26%(5)%361.7 25%379.9 26%(5)%
Net Sales excluding AT&M (1)
$371.6 100%$380.5 100%(2)%$1,431.4 100%$1,484.6 100%(4)%
AT&M (1)
— —%— —%—%— —%2.1 —%(100)%
    Total Net Sales$371.6 100%$380.5 100%(2)%$1,431.4 100%$1,486.7 100%(4)%
*As a percent of Total Net Sales
(1)Sales from our Automation, Test, and Measurement business (AT&M), which was divested effective July 31, 2024, were previously included in the industrial vertical
(2)Beginning in the first quarter of fiscal year 2026, sales to customers related to commercial transportation, previously included in the automotive vertical, are now reflected in the industrial vertical; prior periods have been recast to conform to current period presentation: $8.8 million for the three months ended June 30, 2025 and $29.4 million for the fiscal year ended June 30, 2025
–Automotive includes electronic power steering, electronic braking systems, and body controls
–Medical includes sleep therapy and respiratory care, AED, surgical devices, in vitro diagnostics, image guided therapy, drug delivery/autoinjectors, patient monitoring, and blood separation
–Industrial includes climate controls, public safety, smart metering, off highway equipment/commercial transportation, IoT and factory automation, efficient energy, and automation controls







Condensed Consolidated Statements of Income
(Unaudited)Three Months Ended
(Amounts in Thousands, except Per Share Data)June 30, 2026June 30, 2025
Net Sales$371,573 100.0%$380,472 100.0%
Cost of Sales338,624 91.1%349,991 92.0%
Gross Profit32,949 8.9%30,481 8.0%
Selling and Administrative Expenses17,989 4.9%13,163 3.5%
Restructuring Expense894 0.2%1,971 0.5%
Gain on Disposal(15,015)(4.0)%(1,127)(0.3)%
Operating Income
29,081 7.8%16,474 4.3%
Interest Income515 0.1%196 0.1%
Interest Expense(1,984)(0.5)%(2,776)(0.7)%
Non-Operating Income (Expense), net(1,161)(0.3)%(1,177)(0.4)%
Other Income (Expense), net(2,630)(0.7)%(3,757)(1.0)%
Income Before Taxes on Income26,451 7.1%12,717 3.3%
Provision (Benefit) for Income Taxes17,933 4.8%6,136 1.6%
Net Income
$8,518 2.3%$6,581 1.7%
Earnings Per Share of Common Stock:
Basic$0.35 $0.27 
Diluted$0.35 $0.26 
Average Number of Shares Outstanding:
     Basic24,330 24,552 
     Diluted24,547 24,840 
(Unaudited)Fiscal Year Ended
(Amounts in Thousands, except Per Share Data)June 30, 2026June 30, 2025
Net Sales$1,431,378 100.0%$1,486,727 100.0%
Cost of Sales1,313,910 91.8%1,382,323 93.0%
Gross Profit117,468 8.2%104,404 7.0%
Selling and Administrative Expenses61,155 4.3%50,270 3.4%
Restructuring Expense4,977 0.3%10,990 0.7%
Gain on Disposal(14,721)(1.0)%(2,391)(0.2)%
Operating Income66,057 4.6%45,535 3.1%
Interest Income1,232 0.1%771 0.1%
Interest Expense(8,504)(0.6)%(14,745)(1.0)%
Non-Operating Income (Expense), net(5,564)(0.4)%(5,332)(0.4)%
Other Income (Expense), net(12,836)(0.9)%(19,306)(1.3)%
Income Before Taxes on Income53,221 3.7%26,229 1.8%
Provision (Benefit) for Income Taxes
25,261 1.7%9,245 0.7%
Net Income$27,960 2.0%$16,984 1.1%
Earnings Per Share of Common Stock:
Basic$1.14 $0.68 
Diluted$1.13 $0.68 
Average Number of Shares Outstanding:
     Basic24,501 24,782 
     Diluted24,768 25,017 






Condensed Consolidated Statements of Cash FlowsFiscal Year Ended
(Unaudited)June 30,
(Amounts in Thousands)20262025
Net Cash Flow provided by Operating Activities$72,267 $183,937 
Net Cash Flow used for Investing Activities
(25,947)(14,700)
Net Cash Flow used for Financing Activities(47,050)(160,874)
Effect of Exchange Rate Change on Cash, Cash Equivalents, and Restricted Cash904 2,325 
Net Increase in Cash, Cash Equivalents, and Restricted Cash174 10,688 
Cash, Cash Equivalents, and Restricted Cash at Beginning of Period89,467 78,779 
Cash, Cash Equivalents, and Restricted Cash at End of Period$89,641 $89,467 



(Unaudited)
Condensed Consolidated Balance SheetsJune 30,
2026		June 30,
2025
(Amounts in Thousands)
ASSETS
    Cash and cash equivalents$88,925 $88,781 
    Receivables, net218,840 222,623 
    Contract assets70,497 71,812 
    Inventories 271,906 273,500 
    Prepaid expenses and other current assets42,836 36,027 
    Assets held for sale— 6,861 
    Property and Equipment, net274,192 264,804 
    Goodwill6,191 6,191 
    Other Intangible Assets, net1,921 2,427 
    Other Assets, net
116,762 104,286 
        Total Assets$1,092,070 $1,077,312 
LIABILITIES AND SHARE OWNERS’ EQUITY
    Current portion of long-term debt$8,202 $17,400 
    Accounts payable234,361 218,805 
    Advances from customers 30,672 35,867 
    Accrued expenses58,860 46,489 
    Long-term debt, less current portion108,000 129,650 
    Other long-term liabilities66,843 59,217 
    Share Owners’ Equity585,132 569,884 
        Total Liabilities and Share Owners’ Equity$1,092,070 $1,077,312 








Other Financial Metrics
(Unaudited)
(Amounts in Millions, except CCD)
At or For the
Three Months Ended
June 30,March 31,June 30,
202620262025
Cash Conversion Days (CCD) (1)
82 90 85 
Open Orders (2)
$643 $602 $642 
(1)Cash Conversion Days (“CCD”) are calculated as the sum of Days Sales Outstanding plus Contract Asset Days plus Production Days Supply on Hand less Accounts Payable Days and less Advances from Customers Days. CCD, or a similar metric, is used in our industry and by our management to measure the efficiency of managing working capital.
(2)Open Orders are the aggregate sales price of production pursuant to unfulfilled customer orders. The total reported for June 30, 2025 has been revised to $642 million, from the $702 million originally reported, to more accurately reflect the calculation of open order activity impacting all three verticals.
Select Financial Results of Automation, Test and Measurement
(Unaudited)
(Amounts in Millions)
Three Months EndedFiscal Year Ended
June 30,June 30,
2026202520262025
Net Sales$— $— $— $2.1 
Operating Income (Loss) (1)
$— $1.1 $(0.4)$2.0 
(1)Includes gain (loss) on sale adjustments following the close of the sale on July 31, 2024: ($0.4 million) for fiscal year 2026, $1.1 million for the three months ended June 30, 2025, and $2.4 million for fiscal year 2025.


Reconciliation of Non-GAAP Financial Measures
(Unaudited, Amounts in Thousands, except Per Share Data)
Three Months EndedFiscal Year Ended
June 30,June 30,
2026202520262025
Net Sales Growth (vs. same period in prior year)(2)%(12)%(4)%(13)%
Foreign Currency Exchange Impact1%1%2%1%
Constant Currency Growth(3)%(13)%(6)%(14)%
Selling and Administrative Expenses, as reported$17,989 $13,163 $61,155 $50,270 
Stock Compensation Expense(2,196)(1,991)(8,232)(6,519)
SERP(432)(329)(666)(614)
Acquisition Costs(524)— (524)— 
Adjusted Selling and Administrative Expenses$14,837 $10,843 $51,733 $43,137 
Operating Income, as reported
$29,081 $16,474 $66,057 $45,535 
Stock Compensation Expense2,196 1,991 8,232 6,519 
SERP 432 329 666 614 
Restructuring Expense894 1,971 4,977 10,990 
Asset Impairment (Gain on Disposal) (15,015)(1,127)(14,721)(2,391)
Acquisition Costs524 — 524 — 
Adjusted Operating Income$18,112 $19,638 $65,735 $61,267 
Adjusted Operating Income$18,112 $19,638 $65,735 $61,267 
Depreciation & Amortization10,041 9,582 38,705 36,994 
Adjusted EBITDA$28,153 $29,220 $104,440 $98,261 
Net Income, as reported
$8,518 $6,581 $27,960 $16,984 
Stock Compensation Expense, After-Tax1,665 1,510 6,242 4,944 
Restructuring Expense, After-Tax644 1,474 3,610 8,314 
Asset Impairment (Gain on Disposal), After-Tax(11,387)(1,127)(11,164)(2,086)
Acquisition Costs, After-Tax397 — 397 — 
Adjusted Net Income (Loss)$(163)$8,438 $27,045 $28,156 
Diluted Earnings per Share, as reported$0.35 $0.26 $1.13 $0.68 
Stock Compensation Expense0.07 0.06 0.25 0.19 
Restructuring Expense0.03 0.06 0.15 0.33 
Asset Impairment (Gain on Disposal)(0.47)(0.04)(0.45)(0.08)
Acquisition Costs0.01 — 0.01 — 
Adjusted Diluted Earnings (Loss) per Share$(0.01)$0.34 $1.09 $1.12 



Reconciliation of Non-GAAP Financial Measures
(Unaudited, Amounts in Thousands, except Per Share Data)
Three Fiscal
Months EndedYear Ended
March 31,June 30,
20262026
Net Sales Growth (vs. same period in prior year), Consolidated(6)%(4)%
Non-Recurring Consignment Inventory Sales Impact (1)
7%2%
Normalized Sales Growth, Consolidated1%(2)%
Net Sales Growth (vs. same period in prior year), Medical Vertical(8)%4%
Non-Recurring Consignment Inventory Sales Impact (1)
25%7%
Normalized Sales Growth, Medical Vertical17%11%
(1) Q3’26 included a non-recurring inventory sale of $24 million to a customer for completed programs.